{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=3", "query": { "intervention": "Ruxolitinib", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 291, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T21:00:50.599Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06327100", "title": "Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-Essential Thrombocytosis Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Tasquinimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-08-01", "completion_date": "2031-05-01", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06327100" }, { "nct_id": "NCT04055844", "title": "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myeloid and Monocytic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 14, "start_date": "2020-02-17", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04055844" }, { "nct_id": "NCT06923228", "title": "A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis (AD)" ], "interventions": [ { "name": "CGB-500 Ointment with 1% tofacitinib", "type": "DRUG" }, { "name": "Ruxolitinib 1.5% Cream QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CAGE Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3, "start_date": "2025-04-21", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 1, "location_summary": "Fremont, California", "locations": [ { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06923228" }, { "nct_id": "NCT05750823", "title": "A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonsegmental Vitiligo With Genital Involvement" ], "interventions": [ { "name": "Ruxolitinib Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2023-04-11", "completion_date": "2025-03-06", "has_results": true, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 6, "location_summary": "Fremont, California • Los Angeles, California • Fort Gratiot, Michigan + 3 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Gratiot", "state": "Michigan" }, { "city": "Mayfield", "state": "Ohio" }, { "city": "Pflugerville", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05750823" }, { "nct_id": "NCT04908280", "title": "Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Discoid Lupus Erythematosus" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-05-04", "completion_date": "2024-03-04", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04908280" }, { "nct_id": "NCT02779283", "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "In Vitro Kinase Inhibitor Assay", "type": "DEVICE" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone Sodium Succinate", "type": "DRUG" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 7, "start_date": "2016-01-13", "completion_date": "2018-09-20", "has_results": false, "last_update_posted_date": "2020-05-26", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02779283" }, { "nct_id": "NCT05010005", "title": "A Study of Ruxolitinib and Duvelisib in People With Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphomas", "NK-Cell Lymphomas", "T-cell Prolymphocytic Leukemia", "T-cell Large Granular Lymphocyte Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2021-08-12", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 9, "location_summary": "Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05010005" }, { "nct_id": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Chemosensitivity Assay", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Gene Expression Analysis", "type": "GENETIC" }, { "name": "Genetic Variation Analysis", "type": "GENETIC" }, { "name": "In Vitro Sensitivity-Directed Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "GENETIC", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-11", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551718" }, { "nct_id": "NCT01375140", "title": "Ruxolitinib and Lenalidomide for Patients With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Diseases" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2011-09-22", "completion_date": "2018-09-05", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375140" }, { "nct_id": "NCT04176198", "title": "A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Nusivertib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2019-12-16", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-16T21:00:50.599Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04176198" } ] }